Brokerage firm JMP Securities Downgrades its rating on Cerulean Pharma Inc(NASDAQ:CERU). The shares have been rated Market Perform. Previously, the analysts had a Market Perform rating on the shares. The rating by JMP Securities was issued on Aug 18, 2016.
In a different note, On Aug 30, 2016, Barclays said it Maintains its rating on Cerulean Pharma Inc. In the research note, the firm Lowers the price-target to $5.00 per share. The shares have been rated ‘Overweight’ by the firm.
Cerulean Pharma Inc (CERU) shares turned negative on Mondays trading session with the shares closing down -0.02 points or -1.90% at a volume of 3,38,786. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $1.0799. The peak price level was also seen at $1.0799 while the days lowest was $1.02. Finally the shares closed at $1.03. The 52-week high of the shares is $5.2 while the 52-week low is $0.95. According to the latest information available, the market cap of the company is $28 M.
Cerulean Pharma Inc(CERU) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Earnings per share were $-0.40. Analysts had estimated an EPS of $-0.48.
Several Insider Transactions has been reported to the SEC. On Feb 23, 2016, David R Walt (director) purchased 2,291 shares at $2.08 per share price.Also, On Apr 9, 2015, Llc Cvf, (10% owner) purchased 333,333 shares at $6.00 per share price.
Cerulean Pharma Inc. is a clinical-stage oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs) which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads. Its development-stage pipeline includes CRLX101 and CRLX301. The Company’s lead product candidate CRLX101 is a tumor targeted NDC in Phase II clinical development and has the potential to improve outcomes for patients in combination with other cancer treatments. A Phase II randomized controlled company-sponsored trial is conducted comparing CRLX101 administered in combination with Avastin in patients with renal cell carcinoma. CRLX301 is its second platform-generated clinical candidate is a tumor-targeted NDC in Phase I clinical development. CRLX301 is designed to concentrate in tumors and slowly release its anti-cancer payload docetaxel inside tumor cells.